ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset

Autoimmunity

Volumn 43, Issue 8, 2010, Pages 598-606

  Vaziri Sani, Fariba ^a   Oak, Shilpa ^b   Radtke, Jared ^b   Lernmark, Åke ^a   Lynch, Kristian ^a   Agardh, Carl D ^a   Cilio, Corrado M ^a   Lethagen, Sa L ^a   Rtqvist, Eva ^c   Landin Olsson, Mona ^d   Trn, Carina ^a   Hampe, Christiane S ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF WASHINGTON   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

autoantibodies; Autoimmune diabetes; longitudinal; radioligand binding assay; ZnT8

Indexed keywords

ARGININE; AUTOANTIBODY; TRYPTOPHAN; UNCLASSIFIED DRUG; ZINC TRANSPORTER; ZINC TRANSPORTER 8;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MALE; ONSET AGE;

ADOLESCENT; ADULT; AGE OF ONSET; AUTOANTIBODIES; CATION TRANSPORT PROTEINS; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PROTEIN ISOFORMS; RADIOLIGAND ASSAY; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 78149462294     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903555927     Document Type: Article

References (32)

1. Sherr J, Sosenko J, Skyler JS, Herold KC. Prevention oftype 1 diabetes: The time has come. Nat Clin Pract Endocrinol Metab 2008;4:334-343.
2. Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity 2008;41:11-18.
3. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007;104:17040-17045.
4. Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, Davidson HW, Hutton JC. SlC30A8 is a major target ofhumoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann NY Acad Sci 2008; 1150:256-259.
5. Seve M, Chimienti F, Devergnas S, Favier A. In silico identification and expression of SLC30 family genes: An expressed sequence tag data mining strategy for the characterization of zinc transporters' tissue expression. BMC Genomics 2004;5:32.
6. Wenzlau JM, Moua O, Liu Y, Eisenbarth GS, Hutton JC, Davidson HW. Identification of a major humoral epitope in Slc30A8 (ZnT8). Ann NYAcad Sci 2008;1150:252-255.
7. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881-885.
8. Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW. Novel antigens in type 1 diabetes: The importance ofZnT8. Curr Diab Rep 2009;9:105-112.
9. Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, Walters J, Eisenbarth GS, Davidson HW, Hutton JC. A common non-synonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 2008; 57:2693-2697.
10. Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, Winkler C, Pfluger M, Illig T, Bonifacio E, Ziegler AG. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009;52:1881-1888.
11. Törn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G, Lithner F, Littorin B, Nystrom L, Schersten B, Sundkvist G, Wibell L, Ostman J. Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000;85:4619-4623.
12. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, Harris RA, Robertson JA, Lernmark A. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Compl 2005;19: 238-246.
13. Hampe CS, Hammerle LP, Bekris L, Ortqvist E, Kockum I, Rolandsson O, Landin-Olsson M, Torn C, Persson B, Lernmark A. Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes. J Clin Endocrinol Metab 2000;85: 4671-4679.
14. Mire-Sluis AR, Das RG, Lernmark A. The World Health Organization international collaborative study for islet cell antibodies. Diabetologia 2000;43:1282-1292.
15. Oak S, Phan TH, Gilliam LK, Hirsch IB, Hampe CS. Animal insulin therapy induces a biased insulin antibody response that persists for years after introduction of human insulin. Acta Diabetol2009 [publishedonline].
16. Bingley PJ, Bonifacio E, Mueller PW. Diabetes antibody standardization program: First assay proficiency evaluation. Diabetes 2003;52:1128-1136.
17. Graham J, Hagopian WA, Kockum I, Li LS, Sanjeevi CB, Lowe RM, Schaefer JB, Zarghami M, Day HL, Landin-Olsson M, Palmer JP, Janer-Villanueva M, Hood L, Sundkvist G, Lernmark A, Breslow N, Dahlquist G, Blohmé G; Diabetes Incidence in Sweden Study Group; Swedish Childhood Diabetes Study Group. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 2002; 51:1346-1355.
18. Borg H, Gottsater A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002;51:1754-1762.
19. Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F, Anckaert E, Weets I, Pipeleers DG, Gorus FK. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabetes Care 2000;23:838-844.
20. Jensen RA, Gilliam LK, Törn C, Landin-Olsson M, Karlsson FA, Palmer JP, Kockum I, Akesson K, Lernmark B, Lynch K, Breslow N, Lernmark A. Diabetes Incidence Study in Sweden (DISS) group. Multiple factors affect the loss ofmeasurable Cpeptide over 6 years in newly diagnosed 15-to 35-year-old diabetic subjects. J Diabetes Compl 2007;21: 205-213.
21. Borg H, Marcus C, Sjoblad S, Fernlund P, Sundkvist G. Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies/IA2 antibodies after diagnosis of diabetes. Acta Paediatr 2000;89:46-51.
22. Savola K, Sabbah E, Kulmala P, Vahasalo P, Ilonen J, Knip M. Autoantibodies associated with type I diabetes mellitus persist afterdiagnosis in children. Diabetologia 1998;41:1293-1297.
23. Oak S, Gilliam LK, Landin-Olsson M, Torn C, Kockum I, Pennington CR, Rowley MJ, Christie MR, Banga JP, Hampe CS. The lack ofanti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci USA 2008;105: 5471-5476.
24. Nayak R, Mitra-Kaushik S, Shaila MS. Perpetuation of immunological memory: A relay hypothesis. Immunology 2001;102:387-395.
25. Tillakaratne NJ, Erlander MG, Collard MW, Greif KF, Robin AJ. Glutamate decarboxylases in nonneural cells of rat testis and oviduct: Differential expression of GAD65 and GAD67. JNeurochem 1992;58:618-627.
26. Takeyama N, Ano Y, Wu G, Kubota N, Saeki K, Sakudo A, Momotani E, Sugiura K, Yukawa M, Onodera T. Localization of insulinoma associated protein 2, IA-2 in mouse neuroendo-crine tissues using two novel monoclonal antibodies. Life Sci 2009; 84:678-687.
27. Gyulkhandanyan AV, Lu H, Lee SC, Bhattacharjee A, Wijesekara N, Fox JE, MacDonald PE, Chimienti F, Dai FF, Wheeler MB. Investigation of transport mechanisms and regulation of intracellular Zn2+ in pancreatic alpha-cells. J Biol Chem 2008;283:10184-10197.
28. Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 2004;53: 2330-2337.
29. Gillard P, Vandemeulebroucke E, Keymeulen B, Pirenne J, Maes B, De Pauw P, Vanrenterghem Y, Pipeleers D, Mathieu C. Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipi-ents. Transplantation 2009;87:402-407.
30. Bach JF, Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 2001;19:131-161.
31. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-1920.
32. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects oforal insulin in relatives ofpatients with type 1 diabetes: The diabetes prevention trial-type 1. Diabetes Care 2005;28:1068-1076.